Healthcare provider profile · identity verified

Vanama Yerra, MD

Hospitalist · EDMOND, OK · NPI 1437246717

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	386	62
Furosemide	Furosemide	295	59
Atorvastatin Calcium	Atorvastatin Calcium	285	107
Eliquis	Apixaban	272	47
Gabapentin	Gabapentin	176	62
Amlodipine Besylate	Amlodipine Besylate	133	56
Potassium Chloride	Potassium Chloride	124	42
Metoprolol Tartrate	Metoprolol Tartrate	123	38
Tamsulosin Hcl	Tamsulosin Hcl	116	36
Pantoprazole Sodium	Pantoprazole Sodium	106	51
Clopidogrel	Clopidogrel Bisulfate	99	34
Trazodone Hcl	Trazodone Hcl	97	30
Metformin Hcl	Metformin Hcl	94	29
Lisinopril	Lisinopril	92	46
Carvedilol	Carvedilol	83	31
Duloxetine Hcl	Duloxetine Hcl	83	23
Escitalopram Oxalate	Escitalopram Oxalate	80	16
Mirtazapine	Mirtazapine	76	22
Donepezil Hcl	Donepezil Hcl	75	16
Metoprolol Succinate	Metoprolol Succinate	75	36
Sertraline Hcl	Sertraline Hcl	73	21
Losartan Potassium	Losartan Potassium	68	28
Hydroxyzine Hcl	Hydroxyzine Hcl	67	25
Amiodarone Hcl	Amiodarone Hcl	65	27
Xarelto	Rivaroxaban	62	12
Divalproex Sodium	Divalproex Sodium	61	14
Buspirone Hcl	Buspirone Hcl	58	20
Citalopram Hbr	Citalopram Hydrobromide	56	11
Prednisone	Prednisone	56	28
Levetiracetam	Levetiracetam	55	20
Baclofen	Baclofen	49	suppressed
Ropinirole Hcl	Ropinirole Hcl	49	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	46	13
Tizanidine Hcl	Tizanidine Hcl	45	13
Ondansetron Hcl	Ondansetron Hcl	44	13
Isosorbide Mononitrate Er	Isosorbide Mononitrate	43	20
Quetiapine Fumarate	Quetiapine Fumarate	42	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	41	21
Torsemide	Torsemide	40	15
Famotidine	Famotidine	39	33
Fluoxetine Hcl	Fluoxetine Hcl	39	14
Trulicity	Dulaglutide	39	suppressed
Fluticasone Propionate	Fluticasone Propionate	37	17
Acetic Acid	Acetic Acid	35	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	35	suppressed
Ibuprofen	Ibuprofen	35	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	34	suppressed
Meloxicam	Meloxicam	33	suppressed
Omeprazole	Omeprazole	33	12
Lamotrigine	Lamotrigine	32	suppressed
Latanoprost	Latanoprost	32	suppressed
Ondansetron Odt	Ondansetron	32	13
Doxycycline Hyclate	Doxycycline Hyclate	31	20
Hydralazine Hcl	Hydralazine Hcl	31	20
Olanzapine	Olanzapine	30	suppressed
Bupropion Hcl Sr	Bupropion Hcl	29	suppressed
Memantine Hcl	Memantine Hcl	29	13
Pravastatin Sodium	Pravastatin Sodium	28	suppressed
Montelukast Sodium	Montelukast Sodium	27	13
Colesevelam Hcl	Colesevelam Hcl	26	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	26	suppressed
Simvastatin	Simvastatin	26	12
Sucralfate	Sucralfate	26	suppressed
Cephalexin	Cephalexin	25	19
Tradjenta	Linagliptin	24	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	23	20
Cefdinir	Cefdinir	23	22
Colestipol Hcl	Colestipol Hcl	23	suppressed
Paroxetine Hcl	Paroxetine Hcl	23	suppressed
Glipizide	Glipizide	22	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	22	14
Meclizine Hcl	Meclizine Hcl	22	suppressed
Glipizide Er	Glipizide	21	suppressed
Klayesta	Nystatin	20	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	20	suppressed
Santyl	Collagenase Clostridium Hist.	20	suppressed
Myrbetriq	Mirabegron	19	suppressed
Nystatin	Nystatin	19	suppressed
Valacyclovir	Valacyclovir Hcl	19	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	18	18
Jardiance	Empagliflozin	18	suppressed
Methenamine Hippurate	Methenamine Hippurate	18	suppressed
Midodrine Hcl	Midodrine Hcl	17	suppressed
Movantik	Naloxegol Oxalate	17	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	17	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	16	13
Doxazosin Mesylate	Doxazosin Mesylate	16	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	16	suppressed
Terazosin Hcl	Terazosin Hcl	16	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Carbamazepine	Carbamazepine	15	suppressed
Clotrimazole	Clotrimazole	15	suppressed
Methocarbamol	Methocarbamol	15	suppressed
Azithromycin	Azithromycin	14	13
Chlorzoxazone	Chlorzoxazone	14	suppressed
Doxepin Hcl	Doxepin Hcl	14	suppressed
Entresto	Sacubitril/Valsartan	14	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	14	suppressed
Nystop	Nystatin	14	suppressed
Paliperidone Er	Paliperidone	14	suppressed
Promethazine Hcl	Promethazine Hcl	14	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	14	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	13	suppressed
Amantadine	Amantadine Hcl	13	suppressed
Aripiprazole	Aripiprazole	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Humalog Kwikpen U-100	Insulin Lispro	13	suppressed
Lidocaine	Lidocaine	13	suppressed
Roflumilast	Roflumilast	13	suppressed
Topiramate	Topiramate	13	suppressed
Verapamil Er	Verapamil Hcl	13	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Digoxin	Digoxin	12	suppressed
Droxidopa	Droxidopa	12	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	12	suppressed
Letrozole	Letrozole	12	suppressed
Mounjaro	Tirzepatide	12	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Prednisolone Acetate	Prednisolone Acetate	12	suppressed
Spironolactone	Spironolactone	12	11
Warfarin Sodium	Warfarin Sodium	12	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Bumetanide	Bumetanide	11	suppressed
Fluconazole	Fluconazole	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error